The FDA recently approved Ingrezza (valbenazine) for the treatment of adults with tardive dyskinesia.
Austin Hewlett, PharmD-MBA Candidate
Advertisement
Austin Hewlett received his PharmD and MBA degrees from the University of Florida and also holds a BA in Economics from the University of North Florida. Austin has consulted with independent physician and pharmacy owners to help derive insights from their patient and transaction records. Austin currently consults in the physician, insurer, and PBM space.
Articles by Austin Hewlett, PharmD-MBA Candidate
Advertisement
Latest Updated Articles
- Carving Out a Niche in the Treatment of Tardive Dyskinesia
Published: May 3rd 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
KEYNOTE Trial Data Presented at ESMO 2025 Congress Reiterate Pembrolizumab’s Benefits in NSCLC
3
Court Ruling Highlights Risks of Improper Dose Adjustments
4
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
5
